[go: up one dir, main page]

AR020066A1 - Un polipeptido purificado, util para prevenir la tuberculosis y las composiciones farmaceuticas que contienen dichos polipeptidos y los polinucleotidos quelos codifican - Google Patents

Un polipeptido purificado, util para prevenir la tuberculosis y las composiciones farmaceuticas que contienen dichos polipeptidos y los polinucleotidos quelos codifican

Info

Publication number
AR020066A1
AR020066A1 ARP990101583A ARP990101583A AR020066A1 AR 020066 A1 AR020066 A1 AR 020066A1 AR P990101583 A ARP990101583 A AR P990101583A AR P990101583 A ARP990101583 A AR P990101583A AR 020066 A1 AR020066 A1 AR 020066A1
Authority
AR
Argentina
Prior art keywords
polypeptides
tuberculosis
pharmaceutical compositions
purified polypeptide
polycucleotides
Prior art date
Application number
ARP990101583A
Other languages
English (en)
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/056,226 external-priority patent/US6177614B1/en
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of AR020066A1 publication Critical patent/AR020066A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se revela un polipéptido purificado que comprende una secuencia de aminoácidos que se selecciona entre el grupo que consiste en las secuencias de ID SEQ.Ns 2, 4, 6, 8, 10, 12, 14, 16, 18, 22 y 24, la citada secuencia de aminoácidos puede contener demanera adicional, una o más sustituciones de aminoácidosconservadoras de antígenos de M.Tuberculosis. Dichos polipéptidos de fusion que contienen dos o más antígenos de M.Tuberculosis y los polinucleotidos quecodifican los citados polipéptidos sonut iles para el tratamiento y la prevension de la infeccion de M, Tuberculosis. Los polinucleotidosque contienen de dos a cinco secuencias de codificacion de M. Tuberculosis producen proteínas de fusion recombinantes que conservan la inmunogenicidady l aantigenicidad de sus componentes individuales. Composiciones farmacéuticas formuladas con dicho polipéptidos y dichos polinucleotidos.
ARP990101583A 1998-04-07 1999-04-07 Un polipeptido purificado, util para prevenir la tuberculosis y las composiciones farmaceuticas que contienen dichos polipeptidos y los polinucleotidos quelos codifican AR020066A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/056,226 US6177614B1 (en) 1995-03-16 1998-04-07 Control of floral induction in plants and uses therefor
US09/223,040 US6544522B1 (en) 1998-12-30 1998-12-30 Fusion proteins of mycobacterium tuberculosis antigens and their uses

Publications (1)

Publication Number Publication Date
AR020066A1 true AR020066A1 (es) 2002-04-10

Family

ID=22834762

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP990101583A AR020066A1 (es) 1998-04-07 1999-04-07 Un polipeptido purificado, util para prevenir la tuberculosis y las composiciones farmaceuticas que contienen dichos polipeptidos y los polinucleotidos quelos codifican
ARP080103186A AR067658A2 (es) 1998-04-07 2008-07-22 Un polipeptido inmunogenico, un polinucleotido que lo codifica , las composiciones farmaceuticas que contienen dichos polipeptidos y polinucleotido, los vectores de xpresion, vacunas, un metodo para la preparacion de dicho polipeptido y una celula huesped aislada que expresa dicho polipeptido

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP080103186A AR067658A2 (es) 1998-04-07 2008-07-22 Un polipeptido inmunogenico, un polinucleotido que lo codifica , las composiciones farmaceuticas que contienen dichos polipeptidos y polinucleotido, los vectores de xpresion, vacunas, un metodo para la preparacion de dicho polipeptido y una celula huesped aislada que expresa dicho polipeptido

Country Status (9)

Country Link
US (2) US6544522B1 (es)
EP (2) EP2397555A1 (es)
JP (1) JP4516616B2 (es)
AR (2) AR020066A1 (es)
CO (1) CO5070585A1 (es)
CZ (1) CZ302852B6 (es)
NO (1) NO20120234L (es)
PL (1) PL209260B1 (es)
TW (1) TWI223001B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US7087713B2 (en) 2000-02-25 2006-08-08 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
NZ507378A (en) * 1998-04-07 2002-12-20 Corixa Corp Fusion proteins of mycobacterium tuberculosis antigens and their uses
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
WO2001024820A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
DE60033583T2 (de) * 1999-10-07 2007-09-13 Corixa Corp. CSC, Wilmington Eine mycobacterium tuberculosis kodierende sequenz zur expression von heterologen proteinen
US7009042B1 (en) * 1999-10-07 2006-03-07 Corixa Corporation Methods of using a Mycobacterium tuberculosis coding sequence to facilitate stable and high yield expression of the heterologous proteins
EP2133100B1 (en) * 2000-06-20 2011-10-05 Corixa Corporation MTB32A Antigen of mycobacterium tuberculosis with inactivated active site and fusion proteins thereof
AU2003213118A1 (en) * 2002-02-15 2003-09-09 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US8475735B2 (en) * 2004-11-01 2013-07-02 Uma Mahesh Babu Disposable immunodiagnostic test system
WO2006053871A2 (en) 2004-11-16 2006-05-26 Crucell Holland B.V. Multivalent vaccines comprising recombinant viral vectors
US7608277B2 (en) * 2004-12-01 2009-10-27 Gene Therapy Systems, Inc. Tuberculosis nucleic acids, polypeptides and immunogenic compositions
US7968694B2 (en) * 2005-07-01 2011-06-28 Forsyth Dental Infirmary For Children Tuberculosis antigen detection assays and vaccines
WO2007041539A1 (en) * 2005-09-30 2007-04-12 Transcutaneous Technologies, Inc. Iontophoresis apparatus and method for the diagnosis of tuberculosis
US8708320B2 (en) 2006-12-15 2014-04-29 Air Products And Chemicals, Inc. Splashguard and inlet diffuser for high vacuum, high flow bubbler vessel
HUE031184T2 (en) 2010-01-27 2017-06-28 Glaxosmithkline Biologicals Sa Modified tuberculosis antigens

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5330754A (en) 1992-06-29 1994-07-19 Archana Kapoor Membrane-associated immunogens of mycobacteria
DK79893D0 (da) * 1993-07-02 1993-07-02 Statens Seruminstitut New vaccine
DK79793D0 (da) 1993-07-02 1993-07-02 Statens Seruminstitut Diagnostic test
EP0771322B9 (en) 1993-11-23 2009-08-12 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
DE69625802T2 (de) * 1995-03-13 2003-11-13 The Secretary Of State For Defence, Salisbury Impfstoffe gegen die pest
IL123506A (en) 1995-09-01 2004-12-15 Corixa Corp Polypeptide compounds and preparations for immunotherapy and diagnosis of tuberculosis
CA2230927A1 (en) 1995-09-01 1997-03-13 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6555653B2 (en) * 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use

Also Published As

Publication number Publication date
US7064195B2 (en) 2006-06-20
JP4516616B2 (ja) 2010-08-04
TWI223001B (en) 2004-11-01
US6544522B1 (en) 2003-04-08
EP2383342A1 (en) 2011-11-02
CO5070585A1 (es) 2001-08-28
PL209260B1 (pl) 2011-08-31
JP2009000107A (ja) 2009-01-08
NO20120234L (no) 2000-11-30
CZ302852B6 (cs) 2011-12-14
EP2397555A1 (en) 2011-12-21
AR067658A2 (es) 2009-10-21
US20040013677A1 (en) 2004-01-22

Similar Documents

Publication Publication Date Title
AR020066A1 (es) Un polipeptido purificado, util para prevenir la tuberculosis y las composiciones farmaceuticas que contienen dichos polipeptidos y los polinucleotidos quelos codifican
AR006999A1 (es) Una composición inmunogénica, terapéutica o profiláctica , que comprende un polipéptido omp106 aislado, un anticuerpo aislado que se liga a dicho polipéptido y una vacuna que lo comprende.
DK0409472T3 (da) Knoglemorfogenetisk protein
AR002282A1 (es) Polipeptidos utiles para detectar y/o tratar infestaciones con t. cruzi, composiciones farmaceuticas formuladas con dichos polipeptidos; equipos queincluyen dichos polipeptidos para el diagnostico de dichas infecciones, dna, vectores y celulas recombinantes transformadas con dicho dna.
BR9711123A (pt) Quimeras de leucotoxina-gnrh
BR9915548A (pt) Proteìnas de fusão de interferon-beta e usos
DK0728148T3 (da) Forbedrede immunogene sammensætninger mod humant gastrin 17
DK0479948T3 (da) Sammensætninger og fremgangsmåder til syntese af natriuretisk protein-receptor B og anvendelsesfremgangsmåder
AR006813A1 (es) Peptidos consistentes en 16 a 55 residuos de aminoacido, composicion farmaceutica que comprende a por lo menos uno de dichos peptidos, metodo dediagnostico para la deteccion de celulas t auto-reactivas activadas que utiliza a por lo menos uno de tales peptidos y equipo para pruebas utilizado en dicho
SE9101838D0 (sv) Novel peptides and their use
ATE121754T1 (de) Vakzine gegen bordetella.
AR009600A1 (es) Secuencia de acido nucleico y aminoacidos relacionados con helicobacter pylori y composiciones de vacuna de la misma.
DE69426121D1 (de) Gen grb3-3, variante und ihre verwendungen
EP1279677A4 (en) GD3 MIMETIC PEPTIDES
HUP9900574A2 (hu) Trombin-muteinek mint trombin-inhibítor antidotumok
NO930428L (no) Proteinstrukturen til plantetoksingelonin
DK0463053T3 (da) Fremstilling og anvendelse af anthelmintiske midler og beskyttende immunogener
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
DK0773999T3 (da) OR-1, en orphan-receptor tilhørende kernereceptorfamilien
NO20011263L (no) Moraxella Catarrhalis BASBO34-polypeptider og anvendelser derav
ES2059801T3 (es) Nuevas linfoquinas, secuencias de adn que codifican para estas linfoquinas, y composiciones farmaceuticas conteniendo estas linfoquinas.
EA200100314A1 (ru) Пептидные фрагменты холерного экзотоксина в или энтеротоксина в в качестве адъювантов вакцины
AR018532A1 (es) Proteinas sustancialmente puras que contienen analogos de la beta-lipoproteina (blt); aislados de acidos nucleicos que codifican dichas proteinas yformulaciones farmaceuticas que comprenden las proteinas
DE60036676D1 (de) G-protein-gekoppelter rezeptor-ähnliche proteine
DK43991A (da) Allele varianter af plasmodium falciparum merozoitoverfladeantigen

Legal Events

Date Code Title Description
FB Suspension of granting procedure